Comparable to the RAGNAR trial, the phase 2 trial, FIGHT-207, examined the tumor-agnostic capabilities of pemigatinib as a FGFR1-FGFR3 inhibitor, in three cohorts (Cohort A: FGFR fusions/rearrangements, Cohort B: FGFR actionable single nucleotide variants (SNVs), and Cohort C: FGFR kinase domain mutations and variants of uncertain significance) [111]. The gene discussed is FGFR1; the disease is neoplasm.